Effects of eugenol on nerve and vascular dysfunction in streptozotocin-diabetic rats

M R Nangle, T M Gibson, M A Cotter, Norman E Cameron

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Hyperglycaemia in diabetes mellitus results in oxidative stress and pro-inflammatory changes which contribute to vascular complications including endothelial dysfunction and peripheral neuropathy. The aim of this study was to examine whether treatment with the dominant ingredient of clove oil, eugenol, which has antioxidant and anti-inflammatory properties, could improve diabetic vascular and nerve function in streptozotocin-induced diabetic rats. Intervention treatment was given for 2 weeks following 6 weeks of untreated diabetes. Dose-ranging studies on diabetic deficits in sciatic nerve motor and saphenous nerve sensory nerve conduction velocities gave ED50 values of 28 mg/kg and 9 mg/kg, respectively, conduction velocity being within the non-diabetic range at a dose of 200 mg/kg. Sciatic nerve endoneurial blood flow was 49% reduced by diabetes and this was completely corrected by 200 mg/kg eugenol treatment. Gastric fundus maximum nitrergic nerve-mediated relaxation was 44% reduced by diabetes; eugenol corrected this deficit by 69%. For renal artery rings, maximum endothelium-dependent relaxation to acetylcholine was 51% reduced by diabetes; eugenol corrected this deficit by 60%, with improvements in both nitric oxide and endothelium-derived hyperpolarising factor (EDHF)-mediated vasorelaxation components. Diabetes increased renal artery sensitivity to phenylephrine-mediated contraction, however, this was unaffected by eugenol treatment. Thus, aspects of both vascular and neural complications in experimental diabetes are improved by eugenol, which could have potential therapeutic implications for diabetic neuropathy and vasculopathy.

Original languageEnglish
Pages (from-to)494-500
Number of pages7
JournalPlanta Medica
Volume72
DOIs
Publication statusPublished - 2006

Keywords

  • eugenol
  • Syzygium aromaticurn
  • diabetes
  • nerve conduction
  • pain
  • blood flow
  • gastric fundus
  • neuropathy
  • vascular endothelium
  • nitric oxide
  • EDHF
  • rat
  • ALPHA-LIPOIC ACID
  • CORPUS CAVERNOSUM
  • AUTONOMIC NEUROPATHY
  • GASTRIC FUNDUS
  • BLOOD-FLOW
  • KAPPA-B
  • INHIBITION
  • ANTIOXIDANT
  • AMINOGUANIDINE
  • RESPONSES

Cite this

Effects of eugenol on nerve and vascular dysfunction in streptozotocin-diabetic rats. / Nangle, M R ; Gibson, T M ; Cotter, M A ; Cameron, Norman E.

In: Planta Medica, Vol. 72, 2006, p. 494-500.

Research output: Contribution to journalArticle

Nangle, M R ; Gibson, T M ; Cotter, M A ; Cameron, Norman E. / Effects of eugenol on nerve and vascular dysfunction in streptozotocin-diabetic rats. In: Planta Medica. 2006 ; Vol. 72. pp. 494-500.
@article{6323e01744e148cdb9b0d572d10cf332,
title = "Effects of eugenol on nerve and vascular dysfunction in streptozotocin-diabetic rats",
abstract = "Hyperglycaemia in diabetes mellitus results in oxidative stress and pro-inflammatory changes which contribute to vascular complications including endothelial dysfunction and peripheral neuropathy. The aim of this study was to examine whether treatment with the dominant ingredient of clove oil, eugenol, which has antioxidant and anti-inflammatory properties, could improve diabetic vascular and nerve function in streptozotocin-induced diabetic rats. Intervention treatment was given for 2 weeks following 6 weeks of untreated diabetes. Dose-ranging studies on diabetic deficits in sciatic nerve motor and saphenous nerve sensory nerve conduction velocities gave ED50 values of 28 mg/kg and 9 mg/kg, respectively, conduction velocity being within the non-diabetic range at a dose of 200 mg/kg. Sciatic nerve endoneurial blood flow was 49{\%} reduced by diabetes and this was completely corrected by 200 mg/kg eugenol treatment. Gastric fundus maximum nitrergic nerve-mediated relaxation was 44{\%} reduced by diabetes; eugenol corrected this deficit by 69{\%}. For renal artery rings, maximum endothelium-dependent relaxation to acetylcholine was 51{\%} reduced by diabetes; eugenol corrected this deficit by 60{\%}, with improvements in both nitric oxide and endothelium-derived hyperpolarising factor (EDHF)-mediated vasorelaxation components. Diabetes increased renal artery sensitivity to phenylephrine-mediated contraction, however, this was unaffected by eugenol treatment. Thus, aspects of both vascular and neural complications in experimental diabetes are improved by eugenol, which could have potential therapeutic implications for diabetic neuropathy and vasculopathy.",
keywords = "eugenol, Syzygium aromaticurn, diabetes, nerve conduction, pain, blood flow, gastric fundus, neuropathy, vascular endothelium, nitric oxide, EDHF, rat, ALPHA-LIPOIC ACID, CORPUS CAVERNOSUM, AUTONOMIC NEUROPATHY, GASTRIC FUNDUS, BLOOD-FLOW, KAPPA-B, INHIBITION, ANTIOXIDANT, AMINOGUANIDINE, RESPONSES",
author = "Nangle, {M R} and Gibson, {T M} and Cotter, {M A} and Cameron, {Norman E}",
year = "2006",
doi = "10.1055/s-2006-916262",
language = "English",
volume = "72",
pages = "494--500",
journal = "Planta Medica",
issn = "0032-0943",
publisher = "Georg Thieme Verlag",

}

TY - JOUR

T1 - Effects of eugenol on nerve and vascular dysfunction in streptozotocin-diabetic rats

AU - Nangle, M R

AU - Gibson, T M

AU - Cotter, M A

AU - Cameron, Norman E

PY - 2006

Y1 - 2006

N2 - Hyperglycaemia in diabetes mellitus results in oxidative stress and pro-inflammatory changes which contribute to vascular complications including endothelial dysfunction and peripheral neuropathy. The aim of this study was to examine whether treatment with the dominant ingredient of clove oil, eugenol, which has antioxidant and anti-inflammatory properties, could improve diabetic vascular and nerve function in streptozotocin-induced diabetic rats. Intervention treatment was given for 2 weeks following 6 weeks of untreated diabetes. Dose-ranging studies on diabetic deficits in sciatic nerve motor and saphenous nerve sensory nerve conduction velocities gave ED50 values of 28 mg/kg and 9 mg/kg, respectively, conduction velocity being within the non-diabetic range at a dose of 200 mg/kg. Sciatic nerve endoneurial blood flow was 49% reduced by diabetes and this was completely corrected by 200 mg/kg eugenol treatment. Gastric fundus maximum nitrergic nerve-mediated relaxation was 44% reduced by diabetes; eugenol corrected this deficit by 69%. For renal artery rings, maximum endothelium-dependent relaxation to acetylcholine was 51% reduced by diabetes; eugenol corrected this deficit by 60%, with improvements in both nitric oxide and endothelium-derived hyperpolarising factor (EDHF)-mediated vasorelaxation components. Diabetes increased renal artery sensitivity to phenylephrine-mediated contraction, however, this was unaffected by eugenol treatment. Thus, aspects of both vascular and neural complications in experimental diabetes are improved by eugenol, which could have potential therapeutic implications for diabetic neuropathy and vasculopathy.

AB - Hyperglycaemia in diabetes mellitus results in oxidative stress and pro-inflammatory changes which contribute to vascular complications including endothelial dysfunction and peripheral neuropathy. The aim of this study was to examine whether treatment with the dominant ingredient of clove oil, eugenol, which has antioxidant and anti-inflammatory properties, could improve diabetic vascular and nerve function in streptozotocin-induced diabetic rats. Intervention treatment was given for 2 weeks following 6 weeks of untreated diabetes. Dose-ranging studies on diabetic deficits in sciatic nerve motor and saphenous nerve sensory nerve conduction velocities gave ED50 values of 28 mg/kg and 9 mg/kg, respectively, conduction velocity being within the non-diabetic range at a dose of 200 mg/kg. Sciatic nerve endoneurial blood flow was 49% reduced by diabetes and this was completely corrected by 200 mg/kg eugenol treatment. Gastric fundus maximum nitrergic nerve-mediated relaxation was 44% reduced by diabetes; eugenol corrected this deficit by 69%. For renal artery rings, maximum endothelium-dependent relaxation to acetylcholine was 51% reduced by diabetes; eugenol corrected this deficit by 60%, with improvements in both nitric oxide and endothelium-derived hyperpolarising factor (EDHF)-mediated vasorelaxation components. Diabetes increased renal artery sensitivity to phenylephrine-mediated contraction, however, this was unaffected by eugenol treatment. Thus, aspects of both vascular and neural complications in experimental diabetes are improved by eugenol, which could have potential therapeutic implications for diabetic neuropathy and vasculopathy.

KW - eugenol

KW - Syzygium aromaticurn

KW - diabetes

KW - nerve conduction

KW - pain

KW - blood flow

KW - gastric fundus

KW - neuropathy

KW - vascular endothelium

KW - nitric oxide

KW - EDHF

KW - rat

KW - ALPHA-LIPOIC ACID

KW - CORPUS CAVERNOSUM

KW - AUTONOMIC NEUROPATHY

KW - GASTRIC FUNDUS

KW - BLOOD-FLOW

KW - KAPPA-B

KW - INHIBITION

KW - ANTIOXIDANT

KW - AMINOGUANIDINE

KW - RESPONSES

U2 - 10.1055/s-2006-916262

DO - 10.1055/s-2006-916262

M3 - Article

VL - 72

SP - 494

EP - 500

JO - Planta Medica

JF - Planta Medica

SN - 0032-0943

ER -